Introduction {#sec1}
============

Psoriasis is a chronic inflammatory disease that affects the skin. Studies have shown that psoriasis is not merely a skin problem; psoriasis is linked with various comorbid conditions, especially obesity and metabolic syndrome \[[@cit0001]--[@cit0005]\], which are known risk factors for non-alcoholic fatty liver disease (NAFLD). In the past decade, many studies have drawn attention to comorbid conditions in psoriasis, and preliminary epidemiological data suggest that psoriasis could be associated with the development of NAFLD. Non-alcoholic fatty liver disease includes a spectrum of conditions that range from simple fatty liver, which is relatively benign, to non-alcoholic steatohepatitis (NASH), which can give rise to fibrosis, cirrhosis, and end-stage liver disease \[[@cit0006]\]. Moderate or severe conditions of psoriasis have a high prevalence of chronic liver disease \[[@cit0007]\]. It is hypothesised that components of metabolic syndrome as the most likely pathogenic basis may play a role in the manifestation of NAFLD and psoriasis.

Aim {#sec2}
===

In the present work, our aim was to analyse the prevalence of NAFLD among psoriasis and basic aspects of the relationship between psoriasis and NAFLD.

Material and methods {#sec3}
====================

Study population {#sec3.1}
----------------

Patients with an age of above 18 years and with a clinical diagnosis of psoriasis vulgaris, who were outpatients at the Department of Dermatology, Madras Medical College were recruited for the study over a period of 9 months (from July 2014 to March 2015). We excluded patients who were currently on treatment and also those who received methotrexate, cyclosporine, acitretin, psoralens, or systemic steroids 30 days prior to the day of testing. Subjects who had known documented chronic liver disease (alcohol abuse, hepatitis B or C, haemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis or hepatic malignancy), human immunodeficiency virus (HIV), clinical evidence of malignancy, or other secondary causes of chronic liver disease were also excluded.

Design of study and sample size {#sec3.2}
-------------------------------

This study was designed as a prospective hospital-based observational study in which 250 patients were enrolled. The sample size was determined based on the following assumptions:

1.  17.4% is the previous prevalence reported (our region),

2.  5% absolute precision,

3.  95% confidence interval.

Based on calculation, the samples required were 215 participants.

Anthropometric, clinical, and laboratory variables {#sec3.3}
--------------------------------------------------

Information of the study subjects including age, gender, hypertension, diabetes mellitus, dyslipidaemia, and duration of the psoriasis were collected by a standardized questionnaire. The subject's waist circumference, weight, and height were measured upon enrolment. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in metres (kg/m^2^). Waist circumference was measured according to WHO recommendations \[[@cit0008]\]. Hypertension or high blood pressure was diagnosed if the participant was on anti-hypertensive medications, if a physician had ever told them that they had high blood pressure, or the average of three blood pressure measurements was 130/85 mm Hg. Diabetes mellitus was diagnosed if participants were taking hypoglycaemic medications or had a fasting glucose concentration 110 mg/dl or had been told by a physician that they had diabetes mellitus. All study participants gave written informed consent, and the study protocol was approved by the Institutional Ethics Committee.

Metabolic syndrome was diagnosed by the National Cholesterol Education Program -- Adult Treatment Panel III criteria (NCEP -- ATP III) \[[@cit0009]\]. In accordance with the definition of metabolic syndrome, the patient was classified as having the syndrome if he/she had at least three of the following five risk abnormalities:

1.  waist circumference \> 102 cm in men or \> 88 cm in women,

2.  fasting glucose 110 mg/dl or on treatment,

3.  triglycerides ≥ 150 mg/dl,

4.  HDL men \< 40 mg/dl, women \< 50 mg/dl or on treatment, and

5.  blood pressure 130/85 mm Hg or on treatment.

Venous blood samples were drawn in the morning from each participant after an overnight fast. A panel of blood tests were performed for each participant, which included serum levels of total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum alkaline phosphatase (SAP), serum total protein, albumin, platelet count, viral markers (hepatitis B and C infections), fasting glucose levels, total cholesterol, high density lipoprotein (HDL), and total triglycerides. Low-density lipoprotein (LDL) cholesterol was estimated by the Friedewald's equation (i.e. total cholesterol minus high-density lipoprotein cholesterol minus triglycerides divided by five).

Diagnosis of psoriasis {#sec3.4}
----------------------

The diagnosis of psoriasis was made clinically by the dermatologist and disease severity was assessed using the Psoriasis Area and Severity Index (PASI) \[[@cit0010]\]. The PASI score, ranging from 0 to 72, reflects the erythema, induration, and scaling of the lesions in four body areas (head, trunk, upper limbs, and lower limbs).

Diagnosis of NAFLD {#sec3.5}
------------------

Hepatic ultrasonography scanning procedure was performed in all participants by a qualified radiologist, who was blinded to participant's particulars. The diagnosis of hepatic fatty liver was made on the basis of characteristic sonographic features, i.e. evidence of diffuse hyper-echogenicity of liver relative to kidneys, ultrasound beam attenuation, and poor visualisation of intra-hepatic structures. The fibro scan assesses the fibrosis in liver disease according to the following classification: F0 -- no fibrosis, \< 6.5; F1 -- perisinusoidal fibrosis without septa, 6.6--8.0; F2 -- portal and periportal fibrosis with rare septum, 8.1--12.5; F3 -- portal and periportal fibrosis with many septa \> 12.6; and F4 -- cirrhosis.

Statistical analysis {#sec3.6}
--------------------

Statistical calculations were performed using of SPSS software (version 20.0). Data were expressed as mean ± standard deviation for continuous variables and as numbers and percentages for categorical variables. Statistical analyses included the analysis of variance -- ANOVA (for continuous variables) and Pearson's χ^2^ test (for categorical variables). The association of NAFLD with the psoriasis was assessed by logistic regression analysis. Values at *p* \< 0.05 were considered statistically significant.

Results {#sec4}
=======

Baseline characteristics of the psoriasis cohort {#sec4.1}
------------------------------------------------

To evaluate the prevalence of NAFLD in people with psoriasis, we conducted 9-month hospital-based study. During the enrolment period, 340 adults with psoriasis were eligible for the study and 250 (73.52%) agreed to participate in our study. Their characteristics are summarised in [Table I](#t0001){ref-type="table"}. All participants were diagnosed with psoriasis vulgaris, in which some of the specific types were as follows: 49 had chronic plaque psoriasis, 45 had palmoplantar psoriasis, 38 had scalp psoriasis, 28 patients had psoriasis arthritis, 21 had pustular type, and 7 had nail type.

###### 

Characteristics of psoriasis subjects (*n* = 250)

  Characteristics          Value
  ------------------------ -----------------
  Age                      44.74 ±11.989
  Gender (male)            170 (68%)
  Weight                   62.54 ±9.608
  Height                   158.84 ±7.833
  BMI                      24.772 ±3.611
  Waist circumference      91.53 ±13.910
  Systolic                 120.26 ±15.222
  Diastolic                81.43 ±11.335
  FBS                      114.23 ±25.328
  TGL                      202.87 ±109.762
  Cholesterol              214.04 ±40.969
  HDL                      44.28 ±8.572
  Obese                    46 (18.4%)
  Metabolic syndrome       177 (70.8%)
  Fatty liver              134 (53.6%)
  NAFLD                    113 (45.2%)
  Alcoholic                22 (8.8%)
  Abdominal obesity        120 (48%)
  Hypercholesterolaemia    160 (64%)
  Hypertriglyceridaemia    166 (66.4%)
  Low HDL                  117 (46.8%)
  Hyperglycaemia           132 (52.8%)
  Hypertension             134 (53.6%)
  Diabetes                 133 (53.2%)
  Elevated ALT             110 (44%)
  HBsAg +ve                9 (3.6%)
  Anti-HCV +ve             1 (0.4%)
  AST                      28.15 ±12.009
  ALT                      29.75 ±13.005
  AST/ALT                  1.044 ±0.419
  Duration                 4.14 ±2.696
  Fibro Scan               5.974 ±1.7435
  PASI                     27.80 ±13.494
  S. Bilirubin -- total    0.664 ±0.5997
  S. Bilirubin -- direct   0.304 ±0.1360
  SAP                      68.49 ±24.514
  Serum protein            7.530 ±1.003
  Albumin                  4.239 ±0.4704
  Platelet                 2.7158 ±0.85809

The participants were largely middle aged (44.74 ±11.989) and the majority were overweight (24.772 ±3.611 kg/m^2^) and male (68%, *n* = 170). More than two thirds of the participants (70.8%) met the criteria for diagnosis of metabolic syndrome based on NCEP -- ATP III. Abdominal obesity was detected in 48% of psoriasis patients. Dyslipidaemia was more commonly observed in 96% of patients (abnormal value at least anyone of lipid profile), and 52.8% of patients were hyperglycaemic. 53.6% of psoriatic patients had hypertension, and 44% of the patients presented with elevated ALT levels.

Prevalence and characteristics of psoriasis-associated NAFLD {#sec4.2}
------------------------------------------------------------

The sonographic examination revealed signs of fatty liver (134/250, 53.6%). In 21 of these 134 cases, there was evidence of significant ethanol intake (*n* = 14), chronic hepatitis B infection (HBsAg +ve) (*n* = 6), and chronic hepatitis C (anti-HCV +ve) (*n* = 1). The remaining 113 met the criteria for diagnosis of NAFLD (prevalence: 45.2%).

Psoriasis patients with NAFLD were younger than patients with psoriasis alone, more obese when compared to non-NAFLD patients with psoriasis, more likely to be male and had higher levels of BMI. They also had greater frequency of metabolic syndrome when compared to psoriasis with non-NAFLD and the majority of NAFLD patients had higher serum ALT concentrations. Notably, compared with psoriasis patients with NAFLD had a more severe form of psoriasis than with non-NAFLD according to PASI score (mean ± SD: 32.88 ±13.542 vs. 23.19 ±12.052; *p* \< 0.0001) ([Table II](#t0002){ref-type="table"}).

###### 

Correlation between psoriasis with non-NAFLD and NAFLD

  Characteristics          Psoriasis with NAFLD (*n* = 113)   Psoriasis with non-NAFLD (*n* = 105)   *P*-value
  ------------------------ ---------------------------------- -------------------------------------- -----------
  Age                      42.23 ±11. 004                     46.02 ±12.622                          0.019
  Gender (male)            84 (74.3%)                         64 (61%)                               0.042
  Weight                   63.74 ±9.456                       61.11 ±9.923                           0.046
  Height                   158.85 ±7.480                      157.52 ±8.156                          0.212
  BMI                      25.217 ±3.462                      24.655 ±3.956                          0.265
  Systolic                 122.01 ±13.218                     118.93 ±17.791                         0.147
  Diastolic                81.56 ±11.721                      82.39 ±11.442                          0.596
  FBS                      120.69 ±24.570                     110.70 ±27.273                         0.005
  TGL                      238.18 ±129.895                    172.23 ±83.368                         0.0001
  Cholesterol              217.03 ±43.198                     210.28 ±40.723                         0.237
  HDL                      44.54 ±8.206                       43.43 ±9.038                           0.342
  LDL                      124.23 ±37.242                     132.07 ±34.716                         0.110
  Obese                    16 (14.2%)                         13 (12.4%)                             0.842
  Metabolic syndrome       94 (83.2%)                         69 (65.7%)                             0.005
  Waist circumference      94.07 ±11.401                      88.00 ±15.038                          0.001
  Abdominal obesity        63 (55.8%)                         39 (37.1%)                             0.007
  Hypercholesterolaemia    69 (61.1%)                         66 (62.9%)                             0.889
  Hypertriglyceridaemia    89 (78.8%)                         54 (51.4%)                             0.0001
  Low HDL                  51 (45.1%)                         56 (53.3%)                             0.278
  Hyperglycaemia           76 (67.3%)                         43 (41%)                               0.0001
  Hypertension             65 (57.5%)                         59 (56.2%)                             0.891
  Diabetes                 77 (68.1%)                         45 (42.9%)                             0.0001
  Elevated ALT             66 (58.4%)                         35 (33.3%)                             0.0001
  ALT                      34.21 ±13.666                      26.23 ±11.532                          0.0001
  AST                      32.04 ±13.320                      29.30 ±9.617                           0.084
  AST/ALT                  0.989 ±0.386                       1.258 ±0.500                           0.0001
  Duration                 4.61 ±2.932                        3.69 ±2.339                            0.011
  Fibro Scan               6.596 ±1.852                       5.422 ±1.431                           0.0001
  PASI                     32.88 ±13.542                      23.19 ±12.052                          0.0001
  S. Bilirubin -- total    0.748 ±0.841                       0.672 ±0.335                           0.392
  S. Bilirubin -- direct   0.341 ±0.152                       0.332 ±0.170                           0.703
  SAP                      64.69 ±25.771                      69.87 ±23.355                          0.123
  Serum protein            7.635 ±0.849                       7.430 ±1.176                           0.140
  Albumin                  4.179 ±0.395                       4.262 ±0.476                           0.160
  Platelet                 2.647 ±0.540                       2.813 ±1.173                           0.178

Fibrosis scores of NAFLD patients with psoriasis were higher than non-NAFLD patients with psoriasis. Among the NAFLD patients with psoriasis, 36.2% showed portal and periportal fibrosis with septum (F2--F3). Most of the NAFLD patients with psoriasis (63.8%) showed fibrosis in F1 stage. Cirrhosis of the liver did not occur in any of the NAFLD patients with psoriasis.

Correlation between psoriasis with NAFLD and psoriasis without NAFLD {#sec4.3}
--------------------------------------------------------------------

Univariate logistic regression analysis was performed to explore the mechanisms underlying the correlation between psoriasis and NAFLD in the 218 patients. The significant were observed between NAFLD and non-NAFLD subjects in age, sex, weight, waist circumference, fasting blood sugar, PASI, metabolic syndrome, ALT, duration of psoriasis, fibroscan, direct serum bilirbin, serum protein and statistical significant was not observed in other variables in univariate analysis ([Table III](#t0003){ref-type="table"}).

###### 

Univariate analysis

  Characteristics          *P-*value   OR (95% CI)
  ------------------------ ----------- -----------------------
  Age                      0.020       1.028 (1.004--1.052)
  Gender (male)            0.035       1.856 (1.043--3.301)
  Weight                   0.048       0.972 (0.945--1.0)
  Height                   0.212       0.978 (0.945--1.013)
  BMI                      0.264       0.960 (0.893--1.032)
  Systolic                 0.149       0.987 (0.970--1.005)
  Diastolic                0.595       1.006 (0.983--1.030)
  FBS                      0.006       0.984 (0.973--0.996)
  TGL                      0.0001      0.993 (0.990--0.997)
  Cholesterol              0.237       0.996 (0.990--1.003)
  HDL                      0.341       0.985 (0.955--1.016)
  LDL                      0.111       1.006 (0.999--1.014)
  Obese                    0.699       1.167 (0.532--2.560)
  Metabolic syndrome       0.004       2.581 (1.366--4.879)
  Waist circumference      0.001       0.966 (0.947--0.987)
  Abdominal obesity        0.006       2.132 (1.239--3.669)
  Hypercholesterolaemia    0.785       0.927 (0.536--1.602)
  Hypertriglyceridaemia    0.0001      3.510 (1.939--6.327)
  Low HDL                  0.227       0.720 (0.422--1.227)
  Hyperglycaemia           0.0001      2.962 (1.704--5.148)
  Hypertension             0.843       1.056 (0.617--1.805)
  Diabetes                 0.0001      2.852 (1.640--4.959)
  Elevated ALT             0.0001      2.809 (1.617--4.877)
  ALT                      0.0001      0.951 (0.929--0.973)
  AST                      0.087       0.980 (0.957--1.003)
  AST/ALT                  0.0001      4.889 (2.202--10.852)
  Duration                 0.013       0.877 (0.792--0.972)
  Fibro Scan               0.0001      0.642 (0.533--0.774)
  PASI                     0.0001      0.941 (0.918--0.965)
  S. Bilirubin -- total    0.425       0.805 (0.472--1.373)
  S. Bilirubin -- direct   0.702       0.723 (0.137--3.805)
  SAP                      0.124       1.009 (0.998--1.020)
  Serum protein            0.147       0.816 (0.620--1.074)
  Albumin                  0.168       1.576 (0.825--3.012)
  Platelet                 0.198       1.248 (0.891--1.749)

Another important finding of our study is multivariate analysis, which has not been carried out in previous reports. The variables that were independently associated with NAFLD among patients with psoriasis were hypertriglyceridaemia (OR = 3.174, 95% CI: 1.565--6.438, *p* \< 0.001), hyperglycaemia (OR = 2.495, 95% CI: 1.191--5.227, *p* \< 0.015), fibro scan (OR = 0.692, 95% CI: 0.553--0.867, *p* \< 0.001), PASI (OR = 0.950, 95% CI: 0.922--0.979, *p* \< 0.001), and duration (OR = 0.865, 95% CI: 0.756--0.990, *p* \< 0.035) and gender (OR = 2.681, 95% CI: 1.244--5.778, *p* \< 0.012) ([Table IV](#t0004){ref-type="table"}).

###### 

Multivariate analysis

  Characteristics        *P*-value   AOR (95% CI)
  ---------------------- ----------- ----------------------
  Age                    0.136       1.022 (0.993--1.052)
  Gender (male)          0.012       2.681 (1.244--5.778)
  Weight                 0.069       0.967 (0.933--1.003)
  Abdominal obesity      0.474       1.291 (0.642--2.593)
  Hypertriglyceridemia   0.001       3.174 (1.565--6.438)
  Hyperglycaemia         0.015       2.495 (1.191--5.227)
  Elevated ALT           0.224       1.563 (0.761--3.209)
  Duration               0.035       0.865 (0.756--0.990)
  Fibro Scan             0.001       0.692 (0.553--0.867)
  PASI                   0.001       0.950 (0.922--0.979)

Discussion {#sec5}
==========

The hallmark of NAFLD refers to the accumulation of fat in the liver. Non-alcoholic fatty liver disease is regarded as the hepatic manifestation of metabolic syndrome and the most common form of chronic liver disease throughout world \[[@cit0011]--[@cit0013]\]. The previously well-described risk factors for NAFLD include metabolic syndrome and lifestyle habits, such as fructose consumption and physical activity level, which impact disease severity \[[@cit0014]\]. Recent reports have shown that people with psoriasis may be at greater risk for developing of NAFLD \[[@cit0015], [@cit0016]\].

Non-alcoholic fatty liver disease prevalence has been estimated to be in the 20--30% range in the general population in various countries and is rapidly increasing. The prevalence of NAFLD has become a major public health concern in developed and developing countries \[[@cit0017], [@cit0018]\]. Non-alcoholic fatty liver disease is one such disease that now has potentially enormous public health consequences due to its progression to more severe forms of the disease ranging from steatosis to steatohepatitis (NASH), which, in turn, can progress into cirrhosis and end stage liver disease and finally the need for liver transplantation. The increasing incidence of NAFLD throughout world has contributed to rising numbers of HCC incidents \[[@cit0019]\]. There is also evidence suggesting that NAFLD individuals are at risk of developing cardiovascular events independently of conventional risk factors and metabolic syndrome components \[[@cit0020]\].

Psoriasis is a chronic, inflammatory, immune-mediated skin disease. Both innate and adaptive immunity are crucial in the initiation and maintenance of psoriatic plaques. Non-alcoholic fatty liver disease began to be considered a part of the metabolic syndrome spectrum, and the relationship between NAFLD and psoriasis became grounded in their association with metabolic syndrome and secretion of proinflammatory cytokines. The first report of patients with psoriasis and concomitant hepatic steatosis was unexpectedly found during a survey conducted in 2002, which aimed to evaluate patients with NAFLD. These patients presented with liver abnormalities seen on ultrasonography and underwent a liver biopsy, which revealed hepatic fibrosis. Since then, different population-based surveys have shown a higher prevalence of NAFLD in patients with psoriasis compared with the general population. It was also observed that the PASI was higher in patients with both psoriasis and NAFLD than in those with psoriasis only.

We have conducted a study to determine the prevalence of NAFLD among patients with psoriasis in our region. The present study reports a notable increase in the prevalence of NAFLD when compared with a previous study in 2012 carried out in our region, in which 17% prevalence was reported \[[@cit0021]\]. Our study is the first to confirm that patients with psoriasis are at increased risk for NAFLD, as suggested by previous studies that used the same evaluating measures for fatty liver; however, our study showed that the prevalence of NAFLD was 45.2%, i.e. the prevalence rate of NAFLD is more than 2.5-fold higher. It should be noted that we do not feel the results of our study discredit the possibility of NAFLD prevalence among psoriasis as determined in other studies conducted in Italy, Netherland, and the USA, which demonstrated that the prevalence was 46%, 47%, and 47%, respectively \[[@cit0022]--[@cit0024]\].

Many studies showed that elderly patients are at increased risk of NAFLD with psoriasis even if the skin disease is mild or moderate and not requiring systemic therapy \[[@cit0024], [@cit0025]\]. But an important finding of our study showed that a high prevalence is observed even in middle-aged psoriatic populations; the mean age of patients was 44.02 years.

We observed a significant relationship between NAFLD and gender. NAFLD was more prevalent in male gender than in female gender. High BMI levels were frequent in our NAFLD patients with psoriasis, and this finding confirmed the previous findings \[[@cit0021]\].

It is reported that metabolic syndrome is more common in psoriasis patients \[[@cit0026]\]. We found higher rates of metabolic syndrome among NAFLD than non-NAFLD patients with psoriasis. However, our major finding in this study was that psoriasis with NAFLD was positively correlated with three components of metabolic syndrome: hyperglycaemia, hypertriglyceridemia, and abdominal obesity, but significant correlation was not observed with hypertension and low level of HDL in univariate logistic regression analysis, although the levels of HDL and blood pressure were reported to be higher in psoriasis patients with NAFLD than in those with non-NAFLD.

Although obesity is reported to be highly prevalent among psoriasis patients, we did not find significant correlation between BMI and NAFLD in psoriasis patients. However, we observed a higher number of obese among psoriasis with NAFLD patients than non-NAFLD psoriasis patients. This may be explained by which concluded that the predominant of our psoriasis patients were overweight.

In our study we observed that ALT was increased in psoriasis patients with NAFLD and highly associated with psoriasis. We did not detect any significant association of NAFLD in other liver function tests in our psoriasis patients. Our study found that DM was common in psoriasis patients. We also found that hypercholesterolaemia was not associated with NAFLD patients with psoriasis even though TGL was highly significantly associated with NAFLD patients with psoriasis.

In multivariate analysis, NAFLD was associated with both the severity and duration of psoriasis. We also observed that psoriasis is associated with hyperglycaemia and hypertriglyceridemia. Therefore, it was concluded that NAFLD is related to the duration of the disease, components of metabolic syndrome such hyperglycaemia and hypertriglyceridemia, and closely associated with the development of psoriasis and NAFLD.

Conclusions {#sec6}
===========

Our findings suggest that NAFLD is frequent in patients with psoriasis and is also associated with the duration and severity of the disease. Physicians must be careful of this association and evaluation of NAFLD in patients with psoriasis, but future investigation is required to determine the most appropriate diagnostic and treatment strategies for these patients.
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